Alpha Teknova Inc - נכסים נקיים למניה בודדת TKNO

Significant capital expenditures on new ventures are hindering the business development of Alpha Teknova, Inc. (TKNO), resulting in a current figure of 1.17. The price action history reflects the impact of geopolitical risks and trade conflicts with the East, which have increased raw material procurement costs. Stability is provided by the California-based biotech reagent complex, where automated filling and multi-stage water filtration ensure high product quality.

For Alpha Teknova, Inc., which operates in the specialized reagents segment for gene therapy, the book value determines the internal asset value of the business relative to market quotes. By analyzing the book value per share, an investor sees the remaining net assets after deducting all liabilities, which allows for an assessment of the actual tangible backing of each share and the identification of any overvaluation of the security.